A follow-up study of the JUPITER trial, presented at the American College of Cardiology meeting in Florida last week, showed that statin therapy works best in the presence of inflammation.
A total of 15,548 healthy men and women were randomly assigned to receive either rosuvastatin 20mg or placebo.
At the end of the five-year study, the researchers, from the Brigham and Women's Hospital in Boston, found that participants taking rosuvastatin who achieved an LDL level less than 1.8mmol/L had a 55 per cent reduction in vascular events.
But patients with a high sensitivity C-reactive protein level less than 2mg/L had a 62 per cent reduction in vascular events.
Comment below and tell us what you think